The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism
Open accessThe DOI matches its Crossref record; 138 of the 144 references it cites were found in a registry or an index; 96 of the 238 sources its claims cite were checked for support.
Abstract
Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.
Overview
CoChat Summary
TL;DR
The 2015 European Thyroid Association guidelines define endogenous subclinical hyperthyroidism (SHyper) biochemically as a persistently subnormal serum TSH with normal free thyroxine and triiodothyronine levels, divided into grade 1 (TSH 0.1–0.39 mIU/l) and grade 2 (TSH <0.1 mIU/l). They recommend treating older patients with grade 2 SHyper, considering treatment in older patients with grade 1 SHyper and younger symptomatic patients with grade 2 SHyper, and not treating younger asymptomatic patients with grade 1 SHyper.
Key findings
- SHyper prevalence varies widely, from 0.6 to 16%; in NHANES it was 0.7% with a TSH cutoff <0.1 mIU/l and 1.8% with a cutoff <0.4 mIU/l, and it can be as high as 15% in iodine-deficient subjects >70 years.
- Grade 2 SHyper carries higher risks than grade 1: progression to overt hyperthyroidism was 5–8% per year in grade 2 versus 0.5–0.7% over 7 years in grade 1, and one retrospective study reported progression in 20% of grade 2 versus 6.8% of grade 1 patients over 7 years (p < 0.001).
- Meta-analyses showed increased risks with SHyper, especially grade 2: incident atrial fibrillation HR 2.54 (95% CI 1.08–5.99) for grade 2 and 1.63 (95% CI 1.10–2.41) for grade 1; heart failure HR 1.94 (95% CI 1.01–3.72) for grade 2 and 1.31 (95% CI 0.88–1.95) for grade 1; total mortality HR 1.24 (95% CI 1.06–1.46); CHD mortality HR 1.84 (95% CI 1.12–3.00) for grade 2; fracture HRs were 1.52 (95% CI 1.19–1.93) for hip fracture, 1.42 (95% CI 1.16–1.74) for any fracture, and 1.74 (95% CI 1.01–2.99) for spine fracture.
- Treatment recommendations: treat patients >65 years with grade 2 SHyper (1/++0); consider treatment in patients >65 years with grade 1 SHyper (2/+00); suggest treating patients <65 years with persistent and/or symptomatic grade 2 SHyper (2/+00); and do not recommend treating young asymptomatic patients with grade 1 SHyper (2/+00). ATDs are first choice in young patients with Graves’ disease and grade 2 SHyper and in patients >65 years with Graves’ disease and grade 1 SHyper; RAI or surgery is preferred for older patients with toxic multinodular goitre or toxic adenoma.
Methods
- An ETA task force was formed in 2014 and performed a systematic literature review searching Medline for “subclinical hyperthyroidism” from May 1974 to July 2015, restricted to English-language reports but including translated articles, plus personal files and references.
- The task force used the GRADE system, rating recommendation strength as 1 (strong) or 2 (weak) and evidence quality as +++ (high, level A), ++0 (moderate, level B), or +00 (low, level C); because few randomized controlled trials were available, nonrandomized trials and expert opinions were also considered.
- Draft recommendations were posted on the ETA members-only website for 4 weeks, comments were incorporated, and the final document was approved by the ETA Guidelines Board and Executive Committee.
Limitations
- The paper states that there are no randomized prospective trials demonstrating that treatment of SHyper improves the associated cardiovascular and skeletal risks, and that two European trials were terminated because they did not complete recruitment.
- The paper states that in most prospective studies thyroid function was measured only at baseline, FT3 was measured in only a few cohorts, and the aetiology of hyperthyroidism was not considered.
- Evident from the text: many recommendations rely on observational cohort studies, meta-analyses of individual participant data, and expert opinion, with several recommendations graded weak (2) and/or supported by low-quality evidence (+00); treatment benefit itself remains unproven in randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Valid · 4 Not valid · 86 Not checked · 11 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent retrospective Danish cohort study, which was not included in the meta-analysis by Gencer et al. [75] , reported a trend for increased risk for major adverse cardiac events and HF with increasing degree of hyperthyroidism [77] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Heart Failure
What the sources say
- Disputedcites [77] Selmer C, Olesen JB, Hansen ML, et al: Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014;99:2372-2382.10.1210/jc.2013-418424654753 sourceExperimental — accuracy not yet measured
The Hyperthyroid states results report a trend with increasing hyperthyroidism for all-cause mortality, not for MACE or heart failure. They describe MACE risk as elevated in both subclinical and overt hyperthyroidism, while the discussion says the study could not demonstrate a clear dose-dependent relationship with decreasing TSH. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Radioiodine may induce hypothyroidism and ATDs may increase and reduce the rate of hypothyroidism when given in the week before or after radioiodine treatment, respectively [122] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Potential Adverse Effects during Treatment with ATDs, RAI and Surgery
What the sources say
- Disputedcites [122] Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B: Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007;10;334:514.10.1136/bmj.39114.670150.BE17309884 sourceExperimental — accuracy not yet measured
The Hypothyroidism section reports a risk ratio of 0.76 for hypothyroidism when antithyroid drugs were given before radioiodine treatment, indicating a possible reduction, not an increase; the confidence interval includes no effect. The Discussion also describes reduced hypothyroidism rates with antithyroid drugs given in the week before or after treatment. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess in the elderly, similar to overt hyperthyroidism [52,53] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [52] Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252.10.1056/NEJM1994111033119017935681 sourceExperimental — accuracy not yet measured
The Discussion (p. 3) identifies atrial fibrillation as a manifestation associated with overt hyperthyroidism and finds that low thyrotropin is a risk factor for it in people aged 60 or older. The paper does not establish that cardiovascular symptoms are the most frequent indicators of mild thyroid hormone excess; it defines subclinical hyperthyroidism in an asymptomatic person (p. 1). (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [53] Cappola AR, Fried LP, Arnold AM, et al: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033-1041.10.1001/jama.295.9.103316507804 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“At variance, two recent prospective studies did not find an association between low serum TSH levels and the risk of cognitive impairment and dementia or decreased functional capacity in the elderly [61,62] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Symptoms of Hyperthyroidism, Quality of Life, Cognitive Impairment or Dementia in Patients with SHyper
What the sources say
- Partly supportedcites [61] Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP: Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013;8:e59199.10.1371/journal.pone.005919923554996 sourceExperimental — accuracy not yet measured
The Discussion reports no association between subclinical thyroid dysfunction and cognitive performance or decline in participants aged 70–82 with vascular disease or risk factors. The Methods define low TSH as subclinical hyperthyroidism, so this supports the cognitive portion of the claim. The study did not report prospective risks of dementia or decreased functional capacity; its functional-capacity scores appear only as baseline characteristics in the Results. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [62] Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP; PROSPER Study Group: Subclinical thyroid dysfunction and functional capacity among elderly. Thyroid 2014;24:208-214.10.1089/thy.2013.007123941540 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, hyperthyroidism itself has been associated with a prothrombotic state [78,79] .”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Risk of Stroke
What the sources say
- Partly supportedcites [78] Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J: Thyroid diseases and cerebrovascular disease. Stroke 2005;36:2302-2310.10.1161/01.STR.0000181772.78492.0716179578 sourceExperimental — accuracy not yet measured
The Conclusion says in vivo and in vitro studies suggest increased thrombotic risk in thyrotoxicosis, supporting a possible prothrombotic association. It also says evidence is insufficient to establish increased cardioembolic risk from hypercoagulability, so the claim should not be read as an established clinical association. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [79] Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J: Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 2011;43:653-659.10.1055/s-0031-128316221823062 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
123 more claims · 55 with their cited sources checked
Create a free account to see all 171 claims and every source verdict.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has widely been assumed that these associations are caused by subclinical hyperthyroidism with detrimental effects of excess thyroid hormone, for instance its proarrhythmic effect on the heart leading to AF, despite the fact that serum thyroid hormones are within reference range (1, 13–15, 29, 41, 42).”
From Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study (2016) · cites this paper as [41]
In the citing paper
“The European Thyroid Association recently reviewed these data and published guidelines for the treatment of subclinical hyperthyroidism, which are largely concordant with recommendations presented here (428).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Five meta-analyses assessed the risk of cardiovascular and allcause mortality in patients with SHyper [71,[89][90][91][92][93] .Two did not find a link between SHyper and mortality [89,90] , whereas four other meta-analyses found an association between SHyper and cardiovascular or all-cause mortality”
§ The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism > Cardiovascular Mortality and Coronary Heart Disease Events and Mortality
Reported 5 · recomputed 6
Citations
Cites
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Self-citationLow Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Self-citation
Cited by
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Self-citation2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Self-citationThyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Self-citationThyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515
“1 mIU/l) in patients older than 65 years of age and in younger patients with comorbidities (81,82).”
BackgroundSelf-citationThe physiology of endocrine systems with ageing
van den Beld, A. W., Kaufman, J.-M., Zillikens, M. C., Lamberts, S. W. J., Egan, J. M., & van der Lely, A. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30026-3 · Cited by 349
Udovcic, M., Pena, R. H., Patham, B., Tabatabai, L., & Kansara, A. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-2-55 · Cited by 293
Lee, S. Y., & Pearce, E. N. (2023) · JAMA · doi:10.1001/jama.2023.19052 · Cited by 295
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
ESHRE good practice recommendations on recurrent implantation failure
ESHRE Working Group on Recurrent Implantation Failure, Cimadomo, D., de los Santos, M. J., Griesinger, G., Lainas, G., Le Clef, N., McLernon, D. J., Montjean, D., Toth, B., Vermeulen, N., et al. (2023) · Human Reproduction Open · doi:10.1093/hropen/hoad023 · Cited by 237
“4 mIU/l (subclinical hyperthyroidism) may be considered thyroid dysfunction and require further follow-up and treatment (Biondi et al., 2015; Poppe et al., 2021).”
BackgroundManagement of Graves Thyroidal and Extrathyroidal Disease: An Update
Kahaly, G. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa646 · Cited by 223
Self-citationOsuna, P. M., Udovcic, M., & Sharma, M. D. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-2-60 · Cited by 193
Ceriotti, F., Fernandez-Calle, P., Klee, G. G., Nordin, G., Sandberg, S., Streichert, T., Vives-Corrons, J.-L., & Panteghini, M. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0091 · Cited by 181
Chatzitomaris, A., Hoermann, R., Midgley, J. E., Hering, S., Urban, A., Dietrich, B., Abood, A., Klein, H. H., & Dietrich, J. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00163 · Cited by 173
“Neuroendocrinology (1996) 64(4):257–67.”
BackgroundInfluentialThyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside
Yamakawa, H., Kato, T., Noh, J. Y., Yuasa, S., Kawamura, A., Fukuda, K., & Aizawa, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.606931 · Cited by 212
Atrial fibrillation and hyperthyroidism: A literature review
Reddy, V. Y., Taha, W. S., Kundumadam, S. D., & Khan, M. R. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.07.004 · Cited by 155
“heart disease or bisphosphonate treatment.(1,47)”
Biondi, B., & Cooper, D. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1709318 · Cited by 135
Self-citationThyroid disorders and cardiovascular manifestations: an update
Paschou, S. Α., Bletsa, E., Stampouloglou, P. K., Tsigkou, V., Valatsou, A., Stefanaki, K., Kazakou, P., Spartalis, Μ., Spartalis, E. D., Oikonomou, E. K., et al. (2022) · Endocrine · doi:10.1007/s12020-022-02982-4 · Cited by 154
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00166 · Cited by 112
Self-citationChaker, L., Cooper, D. S., Walsh, J. P., & Peeters, R. P. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02016-0 · Cited by 172
Self-citationSun, J., Yao, L., Fang, Y., Yang, R., Chen, Y., Yang, K., & Tian, L. (2017) · International Journal of Endocrinology · doi:10.1155/2017/8130796 · Cited by 97
Thienpont, L. M., Van Uytfanghe, K., De Grande, L. A. C., Reynders, D., Das, B., Faix, J. D., MacKenzie, F., Decallonne, B., Hishinuma, A., Lapauw, B., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269456 · Cited by 101
“Professional practice guidelines incorporate laboratory testing of the thyroid function in patient care (3-7).”
BackgroundClinical aspects of thyroid function during ageing
Chaker, L., Cappola, A. R., Mooijaart, S. P., & Peeters, R. P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30028-7 · Cited by 94
Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study
Pearce, S. H. S., Razvi, S., Yadegarfar, M. E., Martin-Ruiz, C., Kingston, A., Collerton, J., Visser, T. J., Kirkwood, T. B., & Jagger, C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1935 · Cited by 91
“This has led to suggestions that patients with low TSH should be aggressively treated for hyperthyroidism to avoid these complications despite a complete lack of compelling (level 1) evidence to support the effectiveness of this strategy (1, 41, 42).”
BackgroundSubclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?
Manolis, A. S., Manolis, T. A., Melita, H., & Manolis, A. S. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.02.011 · Cited by 90
The Role of Thyroid Hormones in Heart Failure
Vale, C., Neves, J. S., von Hafe, M., Borges‐Canha, M., & Leite-Moreira, A. F. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06870-4 · Cited by 87
Bednarczuk, T., Brix, T. H., Schima, W., Zettinig, G., & Kahaly, G. J. (2021) · European Thyroid Journal · doi:10.1159/000517175 · Cited by 102
Self-citationCramon, P. K., Winther, K. H., Watt, T., Bonnema, S. J., Bjørner, J. B., Ekholm, O., Grøenvold, M., Hegedűs, L. D., Feldt‐Rasmussen, U., & Rasmussen, Å. K. (2016) · Thyroid · doi:10.1089/thy.2016.0044 · Cited by 86
Self-citationInitial evaluation of thyroid dysfunction - Are simultaneous TSH and fT4 tests necessary?
Schneider, C., Feller, M., Bauer, D. C., Collet, T., da Costa, B. R., Auer, R., Peeters, R. P., Brown, S. J., Bremner, A., O'Leary, P. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196631 · Cited by 76
Sohn, S. Y., Inoue, K., Rhee, C. M., & Leung, A. M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae019 · Cited by 88
Recent Advances in Autoimmune Thyroid Diseases
Yoo, W. S., & Chung, H. K. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.3.379 · Cited by 74
The thyroid gland in postmenopausal women: physiology and diseases
Gietka‐Czernel, M. (2017) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2017.68588 · Cited by 89
“In all groups of patients β-blocking drugs can ameliorate cardiac symptoms [24].”
BackgroundThyroid and heart, a clinically relevant relationship
Corona, G., Croce, L., Sparano, C., Petrone, L., Sforza, A., Maggi, M., Chiovato, L., & Rotondi, M. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01590-9 · Cited by 60
Epidemiology of Thyroid Disorders
Vanderpump, M. P. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-72102-6_6 · Cited by 97
De Grande, L. A. C., Van Uytfanghe, K., Reynders, D., Das, B., Faix, J. D., MacKenzie, F., Decallonne, B., Hishinuma, A., Lapauw, B., Taelman, P., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.274407 · Cited by 54
Ruggeri, R. M., Trimarchi, F., & Biondi, B. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0321 · Cited by 53
Self-citationGuidance in Subclinical Hyperthyroidism and Subclinical Hypothyroidism: Are We Making Progress?
Wiersinga, W. M. (2015) · European Thyroid Journal · doi:10.1159/000438909 · Cited by 58
Carlé, A., Andersen, S. L., Boelaert, K., & Laurberg, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0276 · Cited by 58
Self-citationThyroid disease in the perimenopause and postmenopause period
Uygur, M. M., Yoldemir, T., & Yavuz, D. G. (2018) · Climacteric · doi:10.1080/13697137.2018.1514004 · Cited by 52
Bottani, M., Aarsand, A. K., Banfi, G., Locatelli, M., Coşkun, A., Díaz-Garzón, J., Fernandez-Calle, P., Sandberg, S., Ceriotti, F., & Carobene, A. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1885 · Cited by 46
Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
la Vieja, A. D., & Riesco‐Eizaguirre, G. (2021) · Cancers · doi:10.3390/cancers13050995 · Cited by 50
“These levels can be increased in thyroid hyperplasia, subacute thyroiditis, or Graves’ disease, and in the case of thyroid tumors and/or their metastases [33,34].”
BackgroundBiondi, B., Bartalena, L., Chiovato, L., Lenzi, A., Mariotti, S., Pacini, F., Pontecorvi, A., Vitti, P., & Trimarchi, F. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0511-z · Cited by 44
Self-citationSubclinical Hyperthyroidism: A Review of the Clinical Literature
Tsai, K., & Leung, A. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.02.002 · Cited by 45
Type 1 diabetes and associated autoimmune diseases
Frommer, L., & Kahaly, G. J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i11.527 · Cited by 52
Self-citationGluvic, Z. M., Obradovic, M. M., Stewart, A. J., Essack, M., Pitt, S. J., Samardzic, V. S., Šoškić, S., Gojobori, T., & Isenović, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.758043 · Cited by 47
“Antithyroid therapy and beta-blockers affect heart rate control, even conversion to normal sinus rhythm in about 60% of patients (85, 112, 113).”
BackgroundUpdate on subclinical thyroid dysfunction
Hashimoto, K. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0182 · Cited by 56
“ETA guidelines published in 2015 [90] recommend that severe SCHyper patients aged 65 years or older and those aged younger than 65 years old with symptoms of thyrotoxicosis, whose serum TSH levels are lower than 0.”
BackgroundMethodDecallonne, B., Bartholome, E. J., Delvaux, V., D’haeseleer, M., Sankari, S. E., Seeldrayers, P., Wijmeersch, B. V., & Daumerie, C. (2018) · Acta Neurologica Belgica · doi:10.1007/s13760-018-0883-2 · Cited by 43
“GD treatment is more complex and consists of reversible medical treatment for 12–18 months with thionamides, anti-thyroid drugs (ATDs) interfering with the TPO enzyme and thus thyroid hormone synthesis, or irreversible non-surgical (radioactive iodine) or surgical (thyroidectomy) treatment [19, 20].”
WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?
Nieto, H. R., & Boelaert, K. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0328 · Cited by 46
von Itzstein, M. S., Gonugunta, A. S., Wang, Y., Sheffield, T. Y., Lü, R., Ali, S., Fattah, F. J., Xie, D., Cai, J. X., Xie, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03151-2 · Cited by 39
Müller, P., Leow, M. K., & Dietrich, J. W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.942971 · Cited by 48
Age-Related Hormones Changes and Its Impact on Health Status and Lifespan
Biagetti, B., & Puig‐Domingo, M. (2023) · Aging and Disease · doi:10.14336/ad.2022.1109 · Cited by 49
Vita, R., Bari, F. D., Perelli, S., Capodicasa, G., & Benvenga, S. (2019) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2019.01.001 · Cited by 38
“Therefore, quantitative techniques have been not included in national and international guidelines for the diagnosis and management of hyperthyroidism [1,9,33].”
MethodTreatment of adult Graves’ disease
Corvilain, B., Hamy, A., Brunaud, L., Borson‐Chazot, F., Orgiazzi, J., Hachmi, L. B. S., Semrouni, M., Rodien, P., & Lussey‐Lepoutre, C. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.08.003 · Cited by 40
“[147] Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ.”
BackgroundSalem, J., Shoemaker, M. B., Bastarache, L. A., Shaffer, C. M., Glazer, A. M., Kroncke, B. M., Wells, Q. S., Shi, M., Straub, P., Jarvik, G. P., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4615 · Cited by 35
Metabolic Syndrome, Thyroid Function and Autoimmunity - The PORMETS Study
Raposo, L., Martins, S., Ferreira, D., Guimarães, J. T., & Santos, A. C. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180801125258 · Cited by 39
Expert consensus on diagnosis and treatment for elderly with thyroid diseases in China (2021)
Liu, Y., Shan, Z., & Endocrine Metabolic Diseases Group of the Chinese Geriatrics Society (2021) · Aging Medicine · doi:10.1002/agm2.12165 · Cited by 38
Kostopoulos, G., & Effraimidis, G. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0254 · Cited by 49
“As a general rule, early treatment of subclinical hyperthyroidism is recommended in patients aged 65 or older and/or in the presence of cardiovascular or osteoporosis risk factors (69, 70).”
BackgroundHill, M., Třískala, Z., Honců, P., Krejčí, M., Kajzar, J., Bičíková, M., Ondřejíková, L., Jandová, D., & Sterzl, I. (2020) · Physiological Research · doi:10.33549/physiolres.934523 · Cited by 36
Wang, N., Zheng, B., Wu, T., Tan, L., Lian, Y., Ma, Y., Guo, R., Xu, S., Zeng, L., Xu, W., et al. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1950849 · Cited by 31
Soetedjo, N. N. M., Agustini, D., & Permana, H. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101536 · Cited by 53
Du Puy, R. S., Poortvliet, R. K. E., Mooijaart, S. P., den Elzen, W. P. J., Jagger, C., Pearce, S. H. S., Arai, Y., Hirose, N., Teh, R., Menzies, O., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0567 · Cited by 27
“Currently, these recommend routine or trial treatment in patients older than 65 years with subclinical thyroid dysfunction, although individualized, gradual and closely monitored (60,61).”
Racaru, L. V., Fontan, C., Bauriaud, M., Brillouet, S., Caselles, O., Zerdoud, S., Bastié, D., Vallot, D., Caron, P. J., Bardiès, M., et al. (2017) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000705 · Cited by 30
Negro, R., Attanasio, R., Grimaldi, F., Guglielmi, R., & Papini, E. (2016) · European Thyroid Journal · doi:10.1159/000444482 · Cited by 25
Effects of Hyperthyroidism on Coronary Artery Disease: A Computed Tomography Angiography Study
Beyer, C., Plank, F., Friedrich, G. J., Wildauer, M., & Feuchtner, G. M. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.07.002 · Cited by 26
Global FT4 immunoassay standardization: an expert opinion review
Kratzsch, J., Baumann, N. A., Ceriotti, F., Lu, Z. X., Schott, M., van Herwaarden, A. E., Vieira, J. G. H., Kasapic, D., & Giovanella, L. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1696 · Cited by 28
Long-term thionamide antithyroid treatment of Graves' disease
Azizi, F., Abdi, H., Amouzegar, A., & Moeini, A. S. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101631 · Cited by 31
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 35
Metabolic Syndrome in Thyroid Disease
Iwen, K. A., Oelkrug, R., Kalscheuer, H., & Brabant, G. E. (2018) · Frontiers of hormone research · doi:10.1159/000485996 · Cited by 23
Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Stojković, M., & Žarković, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118094747 · Cited by 25
Modulating Thyroid Hormone Levels in Adult Mice: Impact on Behavior and Compensatory Brain Changes
Niedowicz, D. M., Wang, W., PRICE, D. A., & Nelson, P. T. (2021) · Journal of Thyroid Research · doi:10.1155/2021/9960188 · Cited by 25
Sanyal, D., Ray, S., & Malhi, H. S. (2022) · Endocrine Regulations · doi:10.2478/enr-2022-0033 · Cited by 30
Altered attention networks in patients with thyroid dysfunction: A neuropsychological study
Yuan, L., Luan, D., Xu, X., Yang, Q., Huang, X., Zhao, S., Zhang, Y., & Zhou, Z. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104714 · Cited by 22
Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism
Gencer, B., Cappola, A. R., Rodondi, N., & Collet, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795492 · Cited by 28
Decision Making in Subclinical Thyroid Disease
Evron, J. M., & Papaleontiou, M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.014 · Cited by 27
Design of Hydrogel Particle Morphology for Rapid Bioassays
Shapiro, S. J., Dendukuri, D., & Doyle, P. S. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03728 · Cited by 20
Rosário, P. W., Carvalho, M. U. W. B. D., & Calsolari, M. R. (2015) · Clinical Endocrinology · doi:10.1111/cen.12979 · Cited by 19
Cao, Q., Jiao, Y., Yu, T., & Sun, Z. (2020) · Cardiology Journal · doi:10.5603/cj.a2018.0097 · Cited by 21
Kerp, H., Hönes, G. S., Tolstik, E., Hönes-Wendland, J., Gassen, J., Moeller, L. C., Lorenz, K., & Führer, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.683522 · Cited by 16
Azizi, F., Abdi, H., Cheraghi, L., & Amouzegar, A. (2020) · Thyroid · doi:10.1089/thy.2020.0433 · Cited by 20
“Since the risks of cardiovascular and skeletal diseases and mortality are increased in older subjects with SH (4,6–8), despite the absence of randomized prospective clinical trials, both ATA and ETA have recommended treatment in the elderly with grade 2 SH (10,11).”
InfluentialKim, M., Kim, B. H., Jang, M. H., Kim, J. M., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2019) · Endocrine · doi:10.1007/s12020-019-02137-y · Cited by 17
Epidemiology of Thyroid Disease
Vanderpump, M. P. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.96019-7 · Cited by 18
Stress and Thyroid Function—From Bench to Bedside
Petrowski, K., & Kahaly, G. J. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf015 · Cited by 27
Self-citationChachamovitz, D. S. D. O., rio, P. I. C. D. S. V. A., Silva, S. O. E., Teixeira, L. B. B. D. M., Fagundes, M. L., Vaisman, M., & Teixeira, P. D. F. D. S. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0458 · Cited by 16
Graves’ disease, multinodular goiter and subclinical hyperthyroidism
Lassen, P. B., Kyrilli, A., Lytrivi, M., & Corvilain, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.09.004 · Cited by 23
“[3] Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ.”
BackgroundInfluentialCorona, G., Rastrelli, G., Dicuio, M., Concetti, S., Minnetti, M., Pivonello, R., Isidori, A. M., Sforza, A., & Maggi, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03208-3 · Cited by 19
A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD
Blackaller, G. N., Chavez-Iñiguez, J. S., Carreón-Bautista, E. E., González-Torres, F. J., Villareal-Contreras, M., Barrientos-Ávalos, J. R., Maggiani‐Aguilera, P., Rosales, F. R., Antonio, T. M. J., Fregoso, J. A. G., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.10.016 · Cited by 16
Singh, L. H., Chandra, A. K., Yumnam, S. D., Sarkar, D., Manglem, R. K., Dhabali, T., Mookerjee, S., & Ray, I. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111711 · Cited by 18
Subclinical Hyperthyroidism and Cardiovascular Disease
Kim, H. J., & McLeod, D. S. A. (2024) · Thyroid · doi:10.1089/thy.2024.0291 · Cited by 18
“7,8 We present a narrative review detailing scienti fi c knowledge regarding the clinical aspects of SCHyper and CVD, with a focus on individuals with SCHyper and euthyroidism in the general population.”
Thyroid and cardiovascular diseases
ÖKSÜZ, S. B. T., & Şahin, M. (2024) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5927 · Cited by 21
Lim, H. J., Ahn, S. H., Hong, S., & Suh, Y. J. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.10.1626 · Cited by 16
“However, several studies have demonstrated that subclinical thyroid diseases are associated with increased risk of cardiovascular disease (CVD) (2).”
BackgroundMukherjee, S., Datta, S., & Mandal, S. (2018) · Journal of Thyroid Research · doi:10.1155/2018/9030185 · Cited by 15
“Mild tomoderate pericardial effusionwhichmay also occur during ACS is also seen in cases of subclinical hypothyroidism [6].”
BackgroundDiagnosing and management of thyroid nodules and goiter – current perspectives
Studen, K. B., Domagała, B., Gaberšček, S., Zaletel, K., & Hubalewska–Dydejczyk, A. (2024) · Endocrine · doi:10.1007/s12020-024-04015-8 · Cited by 15
Cooper, D. S., & Samuels, M. H. (2020) · Thyroid · doi:10.1089/thy.2020.0136 · Cited by 11
Self-citationApproach to the Patient With a Suppressed TSH
Praw, S. S., & Brent, G. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac635 · Cited by 15
Peterson, M. E., Dougherty, E., & Rishniw, M. (2024) · American Journal of Veterinary Research · doi:10.2460/ajvr.23.12.0278 · Cited by 13
“9,10 This premise is also supported by a previous study 11 that showed euthyroid cats with TSH-CLIA concentrations 0.03 ng/mL were more likely to develop overt hyperthyroidism within 14 months than cats with TSH-CLIA concentrations > 0.03 ng/ mL.”
ResultInfluentialA systematic review of subclinical hyperthyroidism guidelines: a remarkable range of recommendations
Ursem, S. R., Boelen, A., Bruinstroop, E., Elders, P. J. M., Gussekloo, J., Poortvliet, R. K. E., Heijboer, A. C., & den Elzen, W. P. J. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0036 · Cited by 17
“In 15 of the included guidelines, the risk of progression, as well as cardiovascular and bone risks, was assessed to provide evidence for diagnostic testing and treatment ( 11 , 12, 18 , 21, 21, 22, 24, 25, 26, 27, 29, 30 , 32, 33 , 34 ).”
InfluentialLassen, P. B., Kyrilli, A., Lytrivi, M., Patino, M. R., & Corvilain, B. (2016) · Clinical Endocrinology · doi:10.1111/cen.13237 · Cited by 11
Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis
Perdomo, C. M., García‐Goñi, M., Sancho, L., Paricio, J. J., Lozano, M. D., de la Higuera, M., Currás, M., Arbizu, J., & Galofré, J. C. (2020) · Clinical Endocrinology · doi:10.1111/cen.14308 · Cited by 15
Ibrahim, R. S., El-Mezayen, N. S., Khairy, A., Zaatout, H. H., Hammoda, H. M., & Metwally, A. M. (2020) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.1242 · Cited by 14
Metadata
- Authors
- Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J.
- Affiliations
- Federico II University Hospital (IT)
- University of Insubria (IT)
- Johns Hopkins University (US)
- 4Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
- Aalborg University Hospital (DK)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2015-08-26
- Volume
- 4
- Issue
- 3
- Pages
- 149-163
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC4637513
- OpenAlex
- W1562308323
- Semantic Scholar
- 818f295aa3f0f01a788efe5b483e264f688279b3
- Cited by
- 323
- References
- 144
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 34 · 2023: 27 · 2022: 32 · 2021: 39 · 2020: 40 · 2019: 16 · 2018: 38 · 2017: 30 · 2016: 20 · 2015: 3
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- subclinical hyperthyroidism, Graves' disease, autonomously functioning thyroid nodules, multinodular goiter, thyroid-stimulating hormone, cardiovascular risk, atrial fibrillation, heart failure, fracture, elderly patients, treatment indications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.